Blue Jay Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blue Jay Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$8.58M	Sell	94,454 -10,546	-10%	-$959K	5.85%	6
2017 Q1	$9.22M	Buy	+105,000	New	+$9.34M	4.53%	13
2016 Q4	–	Sell	-137,595	Closed	-$12.7M	–	17
2016 Q3	$12.7M	Sell	137,595 -14,658	-10%	-$1.38M	6.95%	2
2016 Q2	$11.8M	Buy	152,253 +77,253	+103%	+$6.57M	7.78%	4
2016 Q1	$6.19M	Buy	+75,000	New	+$6.1M	3.96%	15
2015 Q4	–	Sell	-139,164	Closed	-$14.7M	–	25
2015 Q3	$14.7M	Buy	139,164 +44,499	+47%	+$5.94M	5.76%	5
2015 Q2	$12.9M	Buy	94,665 +7,165	+8%	+$888K	3.48%	13
2015 Q1	$10.9M	Buy	+87,500	New	+$9.27M	3.83%	20

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blue Jay Capital Management's BMRN Position: Q2 2017 in Review

Blue Jay Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 10% in Q2 2017, selling an estimated $959K and leaving 94,454 shares worth $8.58M. The position accounts for 5.85% of the portfolio, ranked #6.

Blue Jay Capital Management first reported a position in BMRN in Q1 2015 and has held it in 8 quarters since. The position peaked at $14.7M in Q3 2015. 426 funds tracked by Wall St. Rank hold BMRN as of Q2 2017.

Blue Jay Capital Management held 94,454 shares of BioMarin Pharmaceuticals worth $8.58M as of Q2 2017.
Blue Jay Capital Management sold 10,546 BioMarin Pharmaceuticals shares in Q2 2017, an estimated $959K.
BioMarin Pharmaceuticals made up 5.85% of Blue Jay Capital Management's portfolio in Q2 2017, its #6 holding.
Blue Jay Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 8 quarters since.
Blue Jay Capital Management's BioMarin Pharmaceuticals position peaked at $14.7M in Q3 2015.
426 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2017.

Based on Blue Jay Capital Management's 13F filing for Q2 2017, filed 11 Aug 2017.